Targeted Resequencing vs Whole-Genome Sequencing for Large Cohorts: When Are Candidate Regions Enough?

When managing population genomics projects involving hundreds or thousands of samples, researchers face a critical strategic fork: should you sequence the complete genome across all individuals using whole-genome sequencing (WGS), or concentrate your sequencing budget on pre-defined candidate regions via targeted resequencing?

When is targeted resequencing enough? Targeted resequencing is sufficient when candidate genomic regions, validated disease loci, or quantitative trait loci (QTL) intervals are already identified, target panel sizes remain under ~10–50 Mb, and cohort scale reaches hundreds to thousands of samples with budget constraints. By allocating sequencing read throughput strictly to targeted loci, hybrid capture and amplicon panels achieve high coverage depth (100×–500×+) at a fraction of the per-sample cost of WGS, providing superior statistical power for rare variant detection and accurate genotype calling. Conversely, WGS remains indispensable when novel variant discovery across non-coding regions, unanchored structural variant profiling, or genome-wide haplotype phasing is required.

You will find a decision framework, a sample size by target footprint scenario matrix, a cost driver comparison table, and a Go/Adjust/Stop pilot scorecard to validate your project before cohort expansion.

TL;DR

• Targeted resequencing often wins when candidate loci are defined, sample size (N) is high, and deep coverage is required at predictable per-sample costs.
• Whole-genome re-sequencing wins when unconstrained discovery across non-coding space, structural variation, or genome-wide LD profiling is required.
• Run a pilot study first to evaluate capture efficiency, fold-80 penalty, and duplicate rates using our Go/Adjust/Stop scorecard.

Decision Framework: Targeted Resequencing vs Whole-Genome Sequencing

Choosing between targeted resequencing and whole-genome sequencing (WGS) for large population cohorts requires balancing target region footprint, sample size (N), required coverage depth, and total available capital.

1.1 Direct Answer: When Targeted Resequencing is Sufficient

Targeted resequencing represents the optimal strategy under the following project parameters:

• Pre-existing genomic hypotheses: Prior genome-wide association studies (GWAS), QTL mapping, or transcriptomic profiling have narrowed the regions of interest to specific genes, pathways, or linkage disequilibrium (LD) blocks.
• Large cohort size (N ≥ 500): The study aims to screen large numbers of biological or clinical samples where per-sample sequencing expenditure must be minimized without compromising diagnostic sensitivity.
• High coverage depth requirements: Detecting ultra-rare somatic mutations, mosaic variants, or low-frequency germline alleles requires deep fold coverage (e.g., >100× to 500×+) that would be financially prohibitive across whole genomes.
• Routine or standardized screening: The study serves as a screening phase in molecular breeding, population surveillance, or clinical cohort validation where standardized panel content ensures uniform cross-batch comparisons.

For detailed operational guidance on targeted panel options, consult our Targeted Resequencing Service.

1.2 When Whole-Genome Sequencing Remains Indispensable

Whole-genome sequencing remains the gold standard and necessary choice when:

• Hypothesis-free discovery: The genetic architecture of the phenotype is entirely unknown, requiring comprehensive scanning across coding and non-coding regions.
• Structural variation and complex rearrangements: The study focuses on large copy-number variations (CNVs), balanced translocations, retrotransposon insertions, or complex inversions that span beyond probe capture boundaries.
• Unbiased haplotype phasing and genome-wide LD: The project demands genome-wide imputation backbones or fine-scale population structure profiling across unconstrained intergenic regions.

When comprehensive genomic coverage is required, refer to our Whole Genome Re-sequencing Service.

1.3 Key Trade-offs at a Glance

Scenario Matrix: Balancing Sample Size, Target Size, and Coverage Depth

Determining whether targeted resequencing or WGS yields higher return on investment requires evaluating the interaction between target panel footprint (in megabases, Mb), cohort sample size (N), and target depth.

Figure 2. Sample size by target panel footprint and depth matrix for choosing targeted resequencing or WGS.

2.1 The Sample Size × Target Footprint Trade-off

The financial break-even point between targeted capture and WGS shifts as a function of panel size. For small target footprints (<5 Mb), library capture probes account for a minor cost component relative to sequencing reads, making targeted capture exponentially cheaper per sample. As panel size expands beyond 50 Mb (approaching whole-exome scale), the combined cost of custom capture probes, bait synthesis, and sequencing approaches the baseline cost of shallow or standard WGS.

2.2 Coverage Depth Dynamics: High-Fold Capture vs Shallow WGS

In large population cohorts, statistical power for association testing depends on both sample size and genotype accuracy. High-fold targeted resequencing (100×+) virtually eliminates false-positive variant calls and heterozygous dropout within candidate loci. In contrast, low-pass WGS (0.5×–5×) relies on genotype likelihoods and imputation against reference panels, which may introduce uncertainty for rare variants or underrepresented populations. For details on whole-exome strategies, explore our Whole Exome Sequencing Service. For additional perspectives on array vs low-pass vs deep WGS trade-offs, see Arrays vs Low-Pass vs Deep WGS.

2.3 Scenario Matrix for Large Cohort Planning

For comparing panel capture vs PCR-based approaches, see our technical comparison Hybrid Capture vs Amplicon Sequencing.

Biological & Variant Discovery Trade-offs in Large Cohorts

Beyond raw cost calculations, researchers must evaluate how each technology impacts biological discovery, variant sensitivity, and analytical accuracy.

3.1 Rare Variant Sensitivity and Statistical Power

Rare variants (minor allele frequency, MAF < 1%) account for a substantial proportion of missing heritability in complex traits and disease susceptibility. Detecting rare variants in population cohorts requires high read coverage to distinguish true biological single nucleotide polymorphisms (SNPs) and insertions/deletions (indels) from sequencing noise.

• Targeted Resequencing: High coverage depth (100×+) ensures that rare alleles are backed by multiple independent reads across both strands, enabling robust caller performance without heavy reliance on population-level imputation.
• WGS at 30×: While sufficient for common and low-frequency variants, 30× WGS may suffer from stochastic sampling loss at rare heterozygous sites, requiring larger sample sizes to reach equivalent call confidence.

When high-density marker screening is sufficient for known loci, review our SNP Genotyping Service.

3.2 Haplotype Resolution, Phase Capture, and Regulatory Context

Targeted capture protocols successfully isolate specific coding and promoter regions. However, physical capture boundaries can truncate long-range linkage disequilibrium (LD) structures and distant enhancer-promoter interactions. If your research hypothesis relies on identifying long-range haplotypes or non-coding regulatory variants located hundreds of kilobases away from the primary gene body, WGS or supplementary long-read sequencing provides contiguous context that targeted panels cannot capture.

3.3 Limitations in Non-Coding Regions and Novel Locus Discovery

Targeted resequencing is inherently hypothesis-driven. If a causal mutation lies in an unannotated intergenic enhancer, deep intronic splice-altering position, or structural expansion outside the probe capture set, targeted resequencing will fail to detect it. WGS avoids capture bias, providing an immutable genomic baseline that can be re-analyzed in silico as functional annotations evolve.

Economic & Budget Structure Analysis for Large-Scale Cohorts

Budget planning for large-scale population genomics extends beyond flow cell reagent costs. A total cost of ownership (TCO) evaluation must account for upfront panel design, library preparation, sequencing, computational infrastructure, and long-term storage.

Figure 3. Cost driver breakdown showing where targeted resequencing achieves maximum budget efficiency.

4.1 Cost per Sample vs Fixed Assay Setup Costs

• Targeted Resequencing: Involves a fixed upfront cost for custom probe synthesis or multiplex primer design. However, as sample size (N) scales from hundreds to thousands, the initial probe synthesis cost is amortized across the cohort, drastically reducing the marginal cost per sample.
• Whole-Genome Sequencing: Features minimal upfront design costs but incurs high, linear reagent and sequencing costs per sample that do not decrease significantly with sample volume.

4.2 Compute, Storage, and Downstream Bioinformatic Overhead

A major hidden expenditure in population genomics is high-performance computing (HPC) and cloud storage:

• WGS Data Footprint: A cohort of 1,000 WGS samples at 30× depth generates approximately 100 TB of raw FASTQ and aligned BAM files, incurring substantial ongoing cloud storage and re-alignment costs.
• Targeted Resequencing Footprint: The same cohort of 1,000 targeted samples at 100× depth generates less than 2–5 TB of total alignment data, reducing computational processing time from days to hours and lowering storage costs by over 90%.

4.3 Cost Driver Breakdown Comparison

For operational frameworks on managing large-scale cohorts, see Scaling Targeted Resequencing to Large Cohorts.

Operational Roadmap: Transitioning Loci to a Scalable Cohort Panel

Successfully deploying a targeted resequencing panel for large population cohorts requires a structured pipeline from locus definition to quality control.

5.1 Defining Loci Footprints from Prior GWAS, QTL, or Literature

1. Collate Lead Signals: Extract significant lead SNPs or QTL peak intervals from discovery GWAS or literature.
2. Define Linkage Disequilibrium (LD) Windows: Expand target boundaries around lead markers to encompass surrounding LD blocks (r² ≥ 0.8) to ensure all potential causal variants are captured.
3. Include Regulatory Annotations: Incorporate promoter regions, known eQTLs, and conserved non-coding elements flanking the target gene bodies.

5.2 Hybrid Capture Probe Design, GC Uniformity, and Off-Target Minimization

• Mask Repeat Elements: Filter out low-complexity sequences, retrotransposons, and highly repetitive genomic regions during probe selection to minimize non-specific binding.
• Balance GC Content: Adjust probe density and tiling overlap across high-GC (e.g., CpG islands, promoter regions) and low-GC regions to prevent coverage dropouts.
• Optimize Bait Tiling: Utilize 2× or 3× flexible bait tiling across critical exons and active sites to maintain uniform fold coverage.

5.3 Batch Effects, Cross-Run Consistency, and Quality Control Guidelines

In multi-center or longitudinal cohort studies, batch-to-batch variation can introduce systematic biases. Key mitigation practices include:

• Inclusion of Internal Controls: Include bridge samples (standardized reference DNA) across every sequencing run to monitor capture efficiency and allele frequency consistency.
• Standardized QC Metrics: Enforce strict pass/fail thresholds for target specificity (% reads on target > 70%), fold-80 penalty (< 1.5), and duplicate rates (< 15%).

Pilot Validation & Go / Adjust / Stop Scorecard

Before scaling a targeted resequencing panel to thousands of cohort samples, executing a pilot study (24–48 representative samples) is essential to validate capture performance, library complexity, and target uniformity.

Figure 4. Pilot scorecard for evaluating capture efficiency, duplicate rate, and coverage uniformity before scaling.

6.1 Purpose of a Small Pilot Study

A pilot project provides empirical data on capture efficiency, off-target binding, probe competition, and library duplicate rates. Identifying underperforming probes or high duplicate rates during the pilot stage allows for probe re-balancing or protocol adjustments before committing major capital.

6.2 Key Pilot Readout Metrics

Evaluate the following primary performance indicators during pilot review:

1. Mean Target Coverage Depth: Verifies that sequencing throughput meets planned depth targets.
2. Percentage of Target Bases at ≥ 30× Coverage: Measures coverage completeness across all targeted intervals.
3. Fold-80 Penalty: Quantifies coverage uniformity (a value closer to 1.0 indicates perfect uniformity across targets).
4. On-Target Read Ratio: Percentage of total mapped reads aligning directly to target probe coordinates.

6.3 Go / Adjust / Stop Scorecard

For comprehensive study planning guidelines, see our guide Population Genomics Study Design Guide.

FAQs

Next steps: If you are planning a large cohort study and want to evaluate custom panel feasibility or pilot design, you can discuss your project requirements with our technical team.

Planning note: Numerical ranges, sequencing depths, data-volume estimates, cost estimates, pilot sizes, and QC thresholds presented in this article are synthesized from published literature and publicly reported industry practices and are provided for research planning reference only. Actual project specifications, performance metrics, costs, and acceptance criteria may vary substantially with species, genome size, sample quality, target design, sequencing platform, laboratory workflow, cohort size, and study objectives. Project-specific parameters should therefore be confirmed during experimental design and pilot evaluation.

  Related Services

Targeted Resequencing

Rare Variant Association Analysis

Sequencing

Whole Exome Sequencing for Population Genetics

Bioinformatics

Genetic Diversity Analysis

Genome-wide Association Analysis Service

QTL Location Analysis Service

  Download

Long-Read Sequencing: PacBio SMRT vs. Oxford Nanopore

Genome-Wide Profiling of Histone Modifications with ChIP-Seq

How to Choose the Best 16S/18S/ITS Sequencing Method for Your Project?